Finance

Lists
Q910:FRA
Annexin Pharmaceuticals AB (publ)
€1.15
-2.95%
(-0.035) 1D
Sep 10, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for Q910...
Open
€1.15
High
€1.15
Low
€1.15
Mkt. cap
117.26M
Avg. vol.
192.00
Volume
0.00
52-wk high
€2.60
52-wk low
€1.02
No. of employees
4
Open
€1.15
High
€1.15
Low
€1.15
Mkt. cap
117.26M
Avg. vol.
192.00
Volume
0.00
52-wk high
€2.60
52-wk low
€1.02
No. of employees
4
News stories
From web sources and news partners
About Annexin Pharmaceuticals AB (publ)
CEO-
Employees4
Founded2014
Headquarters-
SectorPharmaceutical industry
Websiteannexinpharma.se
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7.05M
8.00M
7.92M
8.48M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.35M
2.26M
2.90M
2.96M
Operating expense
9.40M
10.26M
10.82M
11.56M
Total operating expenses
9.40M
10.26M
10.82M
11.56M
Operating income
-9.40M
-10.26M
-10.82M
-11.56M
Other non operating income
-
-
-
1.00K
EBT including unusual items
-9.90M
-10.52M
-10.52M
-11.56M
EBT excluding unusual items
-9.90M
-10.52M
-10.52M
-11.56M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
127.00K
Net income
-9.90M
-10.52M
-10.52M
-11.56M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
154.00K
231.00K
34.00K
-
Interest expense
-
-
-
-
Net interest expenses
154.00K
231.00K
34.00K
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-9.35M
-10.21M
-10.77M
-11.51M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps